Selecting the available treatment for each cancer patient from genomic context is a core goal of precision medicine, but innovative approaches with mechanism interpretation and improved performance are still highly needed. Through utilizing in vitro chemotherapy response data coupled with gene and miRNA expression profiles, we applied a network-based approach that identified markers not as individual molecules but as functional groups extracted from the integrated transcription factor and miRNA regulatory network. Based on the identified chemoresponse communities, the predictors of drug resistance achieved high accuracy in cross-validation and were more robust and reproducible than conventional single-molecule markers. Meanwhile, as candidate communities not only enriched abundant cellular process but also covered a variety of drug enzymes, transporters, and targets, these resulting chemoresponse communities furnished novel models to interpret multiple kinds of potential regulatory mechanism, such as dysregulation of cancer cell apoptosis or disturbance of drug metabolism. Moreover, compounds were linked based on the enrichment of their common chemoresponse communities to uncover undetected response patterns and possible multidrug resistance phenotype. Finally, an omnibus repository named ChemoCommunity (http://www.jianglab.cn/ChemoCommunity/) was constructed, which furnished a user-friendly interface for a convenient retrieval of the detailed information on chemoresponse communities. Taken together, our method, and the accompanying database, improved the performance of classifiers for drug resistance and provided novel model to uncover the possible regulatory mechanism of individual response to drug.
are usually treated by standard protocols without considering individual responses. 1 Recent studies have indicated that multiple paths-such as the tumor microenvironment, activation of DNA repair pathways and genetic and epigenetic changes of drug target genes associated with drug behavior-could lead to the chemotherapy resistance phenotype and thus result in cancer treatment failure. Moreover, both oncogenic transcription factors (such as MYC and NFKB1) and tumor suppressor gene products (such as P53 and P73) have been demonstrated to modulate cellular responses to anticancer agents, which could induce either transient or acquired resistance. For instance, as one of the well-known transcription factors in mediating a variety of cellular responses, NFKB1 could cause drug resistance through regulating MDR1 expression in cancer cells, 2 and another group has also reported that NFKB1 inhibition contributed to resistance to Cisplatin. 3 In recent years, an increasing number of chemotherapy response markers have been studied by the analysis of highthroughput and multi-omics data. Nevins et al. identified the drug response signatures through scoring each individual gene based on how well its expression pattern could discriminate an individual response to chemotherapy. 4 In addition, Garnett et al. screened a panel of several hundred cancer cell lines with 130 drugs and identified genomic markers of drug sensitivity by combining gene mutation and expression information. 5 More comprehensively, Gray's group systemically analyzed multi-omics molecule profiles (including copy number aberrations, mutation, gene and isoform expression, promoter methylation and protein expression) and precisely detected a series of features that are related to responses to 90 experimental or approved therapeutic agents using least squares-support vector machines and random forest algorithms. 6 Although some of these predictors have shown promising results in a limited number of sample cohorts, the same chemoresponse signatures failed to achieve similar performance in supplemental validation studies. Additionally, genomic markers that were filtered from different cohorts had very little overlap. A further limitation of methods to identify markers without considering the regulatory information is that they lacked relatively detailed insight into the biological mechanisms that underlie chemotherapy response. Thus predictive markers of chemotherapy resistance that have more robust performance, more excellent reproducibility and more comprehensive insights into drug action still remain elusive.
With the rapid development of network biology, more and more studies have started to apply network-based analytic approaches to discover markers for classification of different conditions or samples. Through defining activity score as the aggregate expression of genes for a given subnetwork, Ideker's group made use of greedy algorithms for dissecting subnetwork markers with the highest discriminative scores and gained significant improvement in classification of breast cancer metastasis compared with single gene marker approaches. 7 Moreover, multiple network-based methods have been developed for drug repositioning and prediction of drug response. [8] [9] [10] For example, Dao et al. described a network-based classification algorithm with a color coding technique to discover optimally discriminative subnetwork markers that are associated with the chemotherapy response. 11 They identified optimally subnetwork markers in the protein-protein interaction network based on minimizing the distances of samples from the same class while maximizing the distances of samples from different classes. Furthermore, another group proposed a network-based framework, namely the SMiR-NBI model, to prioritize miRNAs as potential biomarkers characterizing treatment responses of anticancer drugs based on the heterogeneous network connecting drugs, miRNAs and genes. 12 Although the continuous optimization of the methods improved the performance of the predictors, the network marker dissection was only based on gene expression and is insufficient to interpret complex mechanisms that underlie chemotherapy resistance at multiple levels. MicroRNAs (miRNAs) are endogenously expressed and evolutionarily conserved small non-coding RNAs, which function in RNA silencing via base-pairing with complementary sequences within mRNA molecules. 13, 14 As demonstrated in numerous studies, miRNAs not only play significant roles in various cellular processes, such as cell proliferation, cell differentiation and cell death, but also act as tumor suppressors or oncogenes to regulate tumor development. [13] [14] [15] [16] Previous studies have also revealed the possible link between miRNA dysregulation and cancer drug resistance phenotypes. For example, the restoration of miR-34 could render the cells more sensitive to Doxorubicin, Cisplatin, Gemcitabine and Docetaxel 17 through directly targeting BCL2, whose overexpression was demonstrated to be associated with a reduced susceptibility to drug-induced apoptosis. 18 In another case,
What's new?
Selecting the best available treatment for individual cancer patients based on their genomic makeup is a core goal of precision medicine, but better approaches are still needed. Using a network-based approach and in vitro chemotherapy response data coupled with gene and miRNA expression profiles, here the authors identified markers not as individual molecules but as functional groups extracted from the integrated transcription factor and miRNA regulatory network. The network-based algorithm and accompanying database may help identify novel types of drug resistance markers with better predictive performance and improve the understanding of transcriptional and post-transcriptional regulation mechanisms involved in drug resistance.
the suppression of miR-21 using antisense oligonucleotides sensitized MCF7 cells to topotecan 19 and increased the sensitivity of cholangiocytes to gemcitabine. 20 Moreover, the effect of miRNAs on the chemotherapy response was systematically studied by Blower et al. as part of the Molecular Targets Program, which is aimed at elucidating molecular targets and understanding mechanisms of chemoresistance. The results proved the roles of miRNAs in the chemoresistance and filtered a series of drug resistance-associated miRNAs (such as miR-221 and miR-222) by comparing the expression patterns of the miRNAs and the response patterns of the 3089 compounds. 21 Furthermore, Potti's group consolidated the molecular variables, such as ER and HER2 status, with corresponding miRNA and mRNA expression profiles as the optimal strategy for chemotherapy sensitivity prediction. 22 With the goal of understanding complex mechanisms of chemoresponses and developing effective predictors of chemoresistance at the transcriptional and post-transcriptional level, we proposed a simple but efficient method for recognizing specific network communities through integrating chemotherapy response data, gene expression and miRNA expression profiles in the curated transcription factor (TF) and miRNA regulatory network. The identified chemoresponse communities in question are not encoded as individual molecules, but as communities of interacting genes and miRNAs within the network. Applying these chemoresponse communities as features, we achieved highly accurate, robust and reproducible predictors in classifying the sensitive/resistant samples with several machine learning algorithms. At the same time, the resulting chemoresponse communities displayed novel models to interpret chemotherapy responses at the transcriptional and post-transcriptional levels, which embodied many significant biological and pharmacological components, such as CYP3A4, BCL2, MDR1 and has-miR-21. Furthermore, we connected the compounds based on the enrichment of their common chemoresponse communities to exhibit similar chemotherapy response patterns and uncovered potential multidrug resistance (MDR) phenotypes for linked compounds. Finally, an omnibus repository named ChemoCommunity was constructed, which furnishes a user-friendly interface for a convenient retrieval of our findings (freely available at http://www.jianglab.cn/ChemoCommunity/).
Materials and Methods

Selection of the compounds used in this analysis
The cancer cell lines were previously assayed for their responses to a variety of compounds, which were measured by the concentration at which growth is inhibited by 50% (IC 50 ). For each compound, the log 10 (IC 50 ) values were normalized across the entire of cell lines. Cell lines with value of log 10 (IC 50 ) that were greater than l 1 SD were defined as resistant to the compound, whereas those with log 10 (IC 50 ) values that were less than l 2 SD were regarded as sensitive. Cell lines with values for log 10 (IC 50 ) within l 6 SD were considered to be intermediate and were then eliminated from further analysis. The following analysis was performed for compounds that had at least 10 sensitive and 10 resistant cell lines. Of the 20,503 compounds evaluated in Developmental Therapeutics Program (DTP), 5,688 met these criteria, including 38 drugs that were approved by FDA and 30 drugs that were conducted in clinical trials.
Construction of the curated TF-miRNA regulatory network
The integrated regulatory network, including transcriptional and post-transcriptional regulations, was constructed by combining five curated data resources: TRANSFAC, TransmiR, 23 miRTarBase, 24 miRecords 25 and TarBase. 26 The curated human TF-gene regulations were derived from the TRANS-FAC database, which also provides miRNA-gene and TFmiRNA information. The curated human TF-miRNA regulations were obtained from the TransmiR database. The curated human miRNA-gene regulations were obtained from the union of miRecords, TarBase (excluding the FALSE support type of the miRNA-gene interactions) and miRTarBase databases. Within the curated regulatory network, all of the redundant edges were collapsed into a single edge, and all the self-directed edges were pruned from the network. Last, the curated TF-miRNA regulatory network, which comprised 565 TFs, 443 miRNAs, 3,301 target genes, and a total of 11,702 regulations, was finally constructed, to be used for further analysis.
Identification of chemoresponse communities for each compound
A network community, or more precisely a k-clique community, is defined as the union of all k-cliques (complete subgraphs of size k) that can be reached from each other through a series of adjacent k-cliques (where the adjacency means sharing k 2 1 nodes). Through using CFinder software, we acquired entire 3-clique communities from the integrated regulatory network. Given a specific network community C for the compound D, the expression values of the gene and miRNA are each individually normalized to the z-transformed score z ij (i represents molecule in community and j represents cell line), which for each molecule i has l 5 0 and SD5 1 over all cell lines. The individual z ij of each n member molecules in the community are integrated into a composite score, which is designated as the CS (Fig. 1 ).
where Sign () is the sign function and T score () is the statistics of the t test on each gene or miRNA within the network community. According to the composite scores of all of the communities for each compound, a t test was performed between the sensitive and resistant cell lines to filter significantly discriminative communities as a chemoresponse community (the significance level was set to 0.05). In addition,
Tumor Markers and Signatures Figure 1 . Flowchart of the study. First, we made use of chemoresponse profiles to category the sensitive/resistant cell lines and selected available compounds for further analysis. Meanwhile, network communities were extracted from integrated regulatory network that involved curated regulations among TFs, miRNAs, and their targets. Next, the normalized expression values of each gene and miRNA were overlaid on its corresponding molecules in the whole candidate communities and then aggregated into a composite score within the community. For each compound, we gained a list of significant communities whose discriminative potentials were computed with t test based on the composite score between the sensitive and resistant cancer cell lines. [Color figure can be viewed at wileyonlinelibrary.com] false discovery rates (FDR) were used to adjust for multiple testing with the R package "q value." For a specified compound, a cell line was delineated as high-CS, if its CS was larger than the average of the CSs across the 60 cell lines, and the other cell lines were regarded as low-CS. Next, the parameter Effect was calculated for each compound-community association to measure the relative difference in the mean IC 50 from the high-CS to low-CS group. For example, an effect of 0.1 or 10 indicates a 10-fold decrease or increase in the drug concentration, respectively.
Evaluation of the performance of community-based classifiers
Using the leave-one-out methods, one of the samples were designated as "test" data, and the remaining samples were regarded as "training" data, to construct the classifier. Four algorithms including Support Vector Machine, Na€ ıve Bayes, Random Forest, Logistic Regression, and two thresholdselected markers (0.01 or 0.05), were applied to calculate the Hit-Rate (accuracy rate in cross-validation) and area under the ROC curve (AUC) of leave-one-out validation and fivefold cross-validation.
Totally, three "single-molecule" methods were applied to compare the predictive performance with our network-based algorithm: (i) "Differential Expression" filtered significantly differentially expressed molecules between the resistant and sensitive cell lines based on the t test; (ii) "Correlation" identified molecules most associated with drug response variation in a collection of cell lines based on Pearson's correlation between basal gene expression and response; 27 (iii) "ElasticNet Regression" used Elastic Net algorithm to perform linear regression on the drug response against the expression levels of all molecules, employing regularization to enforce sparsity of features and thus learn the most relevant molecules. 5 More precisely, chemoresponse community markers or individual molecule markers were selected using the first data cohort and then tested on the second data cohort to measure the unbiased classification performance. To further assess the marker reproducibility, both community-based and singlemolecule markers were filtered from two independent data cohorts. Here, we applied two strategies for selecting individual molecule markers: (i) the "Single Marker Strategy1" analysis was performed by using the drug response-associated genes and miRNAs detected from the data sets and (ii) the "Single Marker Strategy2" analysis was performed by using the same number of top discriminative genes and miRNAs as the number of genes and miRNAs covered by community markers.
Inference of compound connections based on the common chemoresponse community
To access the relevance among the compounds, the hypergeometric cumulative distribution was used to calculate the significance of each compound-compound pair:
in which C C is the number of overlapping chemoresponse communities of compound X and compound Y, C X is the number of compound X-associated chemoresponse communities, C Y is the number of compound Y-associated chemoresponse communities and NC is the total number of network communities. To visualize the MDR associations more systemically, we connected the detected compound pairs to construct the MDR network. In Figure 6 , the significant relationships (p values 0.05) among the "Approved & Clinical" drugs were collected. We next identified two communities that consisted of drugs from the approved and clinical MDR network, using cFinder. Furthermore, we also measured the extent of similarity among the compounds' sensitivity/resistance profiles with Pearson correlation pairwise, by considering, for each compound, its pattern of IC 50 values across the NCI-60 cell lines (the log values were considered).
Results
Identification of the chemoresponse-related network community
We combined chemotherapy response data, gene expression and miRNA expression profiles with an integrated TFmiRNA regulatory network to develop robust network community markers of chemical sensitivity. The compound concentrations that were required for IC 50 of 60 cell lines for 20,503 compounds were obtained from the NCI-60 project. 28 For each compound, cell lines with log 10 (IC 50 ) at least 1 SD above the mean were defined as resistant to the compound, whereas those with log 10 (IC 50 ) at least 1 SD below the mean were regarded as sensitive. Finally, the most resistant and sensitive cell lines were categorized for each compound and 5,688 compounds were reserved for future study. Moreover, the gene and miRNA expression profiles of 60 cancer cell lines previously reported by Liu et al. 29 were acquired from GEO database (GSE22821), which measured the expression levels of 21,000 genes and 723 miRNAs, respectively (Supporting Information, Table S1 ). To obtain an integrated regulatory network, a pooled regulation set comprising TFmiRNA, TF-gene and miRNA-gene were assembled from various curated data resources. We next mapped the genes and miRNAs that were assayed in the expression profile to the curated TF-miRNA regulatory network and finally obtained the expressed subnetwork in which each component owns its expression value. This subnetwork was used for further analysis, which comprised 553 TFs, 308 miRNAs, 2,803 target genes and a total of 9,582 regulations (Supporting Information, Table S2 ).
In the next step, we retrieved 40 directed network communities that consisted of 617 genes and 95 miRNAs from the identified expressed subnetwork using CFinder. 30 In total, 36/40 of the identified network communities were enriched in known biological processes of several annotation resources (such as Gene Oncology, KEGG and BIOCARTA; Hypergeometric test with p values of 0.05). The results of the enrichment analysis revealed that these communities not only cover fruitful biological effects (such as response to stimulus, cell death, cell proliferation, cell cycle and metabolism or immune system) but also include many known drug carriers, enzymes and transporters (Supporting Information, Table S3 ). Penetrating more deeply, we discovered that these network communities are tightly linked with the pathogenesis of cancer; 32 out of 40 network communities contained at least one known cancer-related gene and all of the 95 miRNAs collected in the network community were reported to be implicated in the progression of cancer. Pathway enrichment analysis has also indicated that many network communities have been significantly involved in the cancer pathway, such as "Acute myeloid leukemia," "Bladder cancer" and "Pathways in cancer," and others ( Supporting Information, Fig. S1 ). With an abundance of biological and pharmacological properties, the network community possesses the potency to portray the mode of action (MoA) of the chemicals and regulatory mechanisms that underlie response to compounds.
To further search for communities that were highly discriminative of chemotherapy sensitivity, we overlaid the normalized expression values of each gene and miRNA on its corresponding molecules in all of the candidate communities. For each compound, the gene and miRNA components within the community were aggregated and the discriminative potential of a candidate community was computed with the t test based on the composite score between the sensitive and resistant cancer cell lines. Significantly discriminative communities (p values 0.05) were regarded as chemoresponse communities.
The identified chemoresponse communities for each compound were then applied to predict drug sensitivity and to interpret the mechanism underlying chemoresponse. The detailed identification process is illustrated in Figure 1 and the section of "Materials and Methods." As a result, the research discovered 91,550 significant compound-community associations (p values 0.05; Supporting Information, Fig. S2 and Supporting Information 2).
In contrast to conventional expression-alone analysis, many functional genes and miRNAs whose expression is not differentially expressed were involved in the chemoresponse community. Overall, 97.0 6 3.9 and 77.7 6 15.6% (l 6 SD) of the chemoresponse communities comprised at least one gene and miRNA that were not significantly differentially expressed (t test p values > 0.05) in their responses to chemotherapy, respectively (Fig. 2a) . Further analysis revealed that only the average of 13.2% genes and 29.9% miRNAs in the corresponding chemoresponse communities across the entire 5,688 compounds was significantly differentially expressed. However, for 81.6% and 75.1% of the compounds, the proportions of differentially expressed molecules of chemoresponse communities were higher than that of the entire set of molecules (Fig. 2b) , where 2,462 and 2,374 compounds' chemoresponse communities were significantly enriched with differentially expressed genes and miRNAs (hypergeometric test p values of 0.05), respectively. Many well-established markers of chemotherapy response were not present in the genomic signatures from conventional expression-alone analysis but played a central role in the chemoresponse community by interconnecting many expression-responsive molecules. For example, significant community C27 could be employed to predict the response to curcumin (community-based p values 5 0.032). Its nondiscriminative component miR-15a (single-based p values 5 0.715) was validated to be upregulated in curcumin-treated MCF-7 cells 31 and mediated SMAD3 that was differentially expressed (single-based p values 5 0.026) to Fig. S3 ). These results implied that our community-based approach could collect nondiscriminative but significant regulators compared with conventional single-molecule markers methods.
Chemoresponse communities increase the classification accuracy, robustness, and reproducibility of drug resistance Significant network communities of each compound might be considered to be putative markers for chemotherapy resistance that were based on the aggregate behavior of community components instead of a single gene or miRNA. This feature is a distinct departure from conventional single marker predictors, which lack functional insight and possess inferior reproducibility. 7 To make use of these chemoresponse community markers for classification, the normalized expression levels of genes and miRNAs in each community were integrated to calculate a community composite score. These composite scores were then applied as feature values to construct chemoresponse classifiers for each compound.
To evaluate the classification performance of the community markers, we employed the technique of leave-one-out within the data set, based on the support vector machine. We also analyzed the classifier using the AUC metric to capture the performance over the entire range of sensitivity/specificity values. As shown in Figures 3a and 3b , 92.97% (5228 out of 5688) compounds achieved excellent performance (AUC > 0.8 or hit-rate > 0.8) based on the significant chemoresponse community markers. To further show that the performance was not dependent on the chosen threshold criteria or classification algorithm, we tested the chemoresponse community markers based on leave-one-out validation and fivefold cross-validation with different thresholds (community-based p values 5 0.01 and 0.05) and methods (Na€ ıve Bayes, Random Forest and Logistic Regression; Supporting Information, Figs. S4 and S5). These results reveal that the community-based classifiers are suitable for most of compounds and do not depend on the filtering thresholds and classification algorithms (all these results were provided in the Supporting Information 3).
In the above leave-one-out cross-validation, the community features themselves were identified using all of the samples before classification, which introduced possible circularity into the validation procedure. To examine the robustness of the classifier and achieve an unbiased evaluation of the performance, we identified the chemoresponse community markers that were selected from one cohort of NCI-60 cell lines and then examined the constructed predictors of chemotherapy resistance on the other independent cohort. As a result, the average of the AUC metric across 5,688 compounds was 0.966, in which 5,661 compounds acquired a high accuracy (AUC > 0.8). This cross-data cohort analysis was also adopted for individual molecule markers according to the "Differential Expression," "Correlation" and "ElasticNet Regression" analysis, respectively. The results revealed that community markers remained to gain consistent performance for most of the compounds, but the results from single markers fluctuated wildly and lacked robustness (Fig. 3c and Supporting Information,  Fig. S6a) .
Next, we verified the consistency between the chemoresponse community markers for each compound detected from the two data cohorts using our community-based approach. As illustrated in Figure 3d and Supporting Information, Figure S6b, the average Szymkiewicz-Simpson coefficient between the data sets for community markers across 5,688 compounds was 0.910, which were more reproducible than that of individual markers that were selected without network information. Unlike the conventional individual markers, chemoresponse community markers are highly structured molecule groups that could involve genes and miRNAs with low discriminative potential (e.g., those that are not differentially expressed), because they are required to interconnect many higher scoring molecules and maintain the community's integrity. This property can increase the predictive performance of the identified markers and discover potential disease-causing molecules.
Chemoresponse communities elucidate the potential regulatory mechanism of chemoresistance These chemoresponse communities were further characterized with respect to both the functional annotations of their components and the biological effects of their associated compounds. The analysis revealed that the chemoresponse community covers a broad diversity of cellular processes in response to chemotherapy. In some cases, the known MoAs of compounds and the biological processes in their associated chemoresponse communities agreed well (Fig. 4) . For example, everolimus is an mTOR inhibitor and immunosuppressive agent, which can lead to a blockage in the progression of cells from G1 into S phase and subsequently induce cell growth arrest and apoptosis. 32 Correspondingly, its chemoresponse communities are annotated with the biological processes of "cell cycle," "cell death" and "immune system." Similarly, tamoxifen is known as a selective estrogen receptor modulator, 33 which matched the component annotations of its corresponding chemoresponse communities (which are enriched in the functional terms of "hormone" and "cell proliferation"). On the basis of functional exposition, we discovered that compound indications and allied chemoresponse community annotations were consistent in the light of current biological and pharmacological understanding.
Moreover, most of the components and regulations that are involved in the detected chemoresponse communities have been demonstrated to be related to the chemotherapy resistance of associated compounds in the previous works. These chemoresponse communities not only contained known cancer genes but also included drug metabolismrelated enzymes. Taking Tamoxifen as an example, its 13 out of 19 significant chemoresponse communities were found to contain at least one known gene or miRNA, which play virtual roles in the underlying mechanism of chemoresistance. Among these chemoresponse communities, C28 was found to be significantly associated with Tamoxifen resistance (p values 5 0.024 and effect 5 1.662), where its two cancerrelated genes-EGR1 and NFKB1-have been validated to impact the response to Tamoxifen. [34] [35] [36] In the other instance, we discovered the association between C38 and Tamoxifen (p values 5 0.003, and effect 5 1.773), which provides insight into the interplay between the drug metabolism enzyme CYP3A4 and the cellular machinery in mediating chemotherapy sensitivity. As an important enzyme that catalyzes many reactions in drug metabolism (especial for tamoxifen 37 ), CYP3A4 was reported to be an effect mediator in the response to tamoxifen, whose bioavailability could be enhanced through inhibiting the CYP3A4. 38 As the most plentiful network community, C00 includes 78 miRNAs, 136 TFs and 437 target genes (a total of 2002 regulations) and has been found to be significantly linked with chemotherapy resistance to all of the drugs (yellow circle in Fig. 5 ). As shown in Figure 5 , a pool of regulations that associated with cisplatin resistance were collected in the C00, which indicated that the chemoresponse community could comprehensively explain the mechanism of chemoresistance from a transcriptional and post-transcriptional standpoint. Notably, the common chemoresponse community could present distinct regulatory pathways for different responses to compounds. For example, the primary mechanisms of mediating the resistance to methotrexate (MTX) involved in the C00 are dependent on miR-215 and miR-24. These two miRNAs could control the response to MTX through the direct targeting of DHFR. 39, 40 On the other hand, multiple miRNA-driven pathways in C00 participate in controlling the resistance to bortezomib. [41] [42] [43] [44] For instance, under the regulation of MYC, repressed miR-125b-5p could sensitize lymphoma cells to bortezomib. 43 Similarly, the cell survival of MYC-driven tumors could be improved by miR34a under treatment with bortezomib, based on its ability to reduce p53 levels. 44 Chemoresponse communities link compounds to uncover multidrug resistance associations Multidrug resistance is a phenomenon whereby human tumors that acquire resistance to one type of therapy are found to be resistant to several other drugs whose structures and mechanisms of action could be completely different. 45, 46 It could be assumed that cross resistance between two compounds tends to share analogous regulatory pathways and response patterns. In other words, if two compounds possess multiple common regulatory pathways, then the MDR phenotype would occur between them. 46, 47 To uncover the potential relevance of the experimental compounds systematically, we enumerated all the possible compound-compound pairs across the entire 5,688 compounds based on the available chemoresponse community annotations, expressing as an enrichment of the co-occurring communities that were more common than expected by chance. A total of 2,310,038 significant compound-compound associations were finally identified (enrichment p values 0.05; see ChemoCommunity database for all associations), in which 259 links were potential MDR connections among 68 "Approved & Clinical" compounds. Notably, 5 of the top 10 links among "Approved & Clinical" drugs (rank by significance) have been validated in previous research (Supporting Information, Table S4 ).
One of the notable examples is the mitomycin and MTX pair (enrichment p values 5 4.38 3 10 25 ). Both these compounds are well-known antineoplastic drugs, which possess immunosuppressant properties and prevent DNA synthesis through causing the cross-linking of DNA 48 and inhibiting folic acid reductase, 49 respectively. Multiple clinical cases have demonstrated that they are mutually alternative medicines for advanced and metastatic breast cancer. 50, 51 Additionally, a significant correlation between mitomycin and MTX across 60 cell lines based on the IC 50 values (correlation coefficient 5 0.528 and correlation p values 5 1.44 3 10 25 ) indicated that they presented similar patterns of chemotherapy response. Notably, the MDR association between these two drugs has been proven in cancer cell line studies and clinical tumor treatments. A previous clinical report described that a 32-year-old man with multiple pulmonary metastases from a giant cell tumor of bone failed to respond to high-dose MTX and received mitomycin C in the following treatment but without response. 52 A network graph is conducive to visualize the novel and confirmed MDR associations. Each of the compounds was connected to another compound if their enrichment results were significant, and a multidrug resistance network for all of the "Approved & Clinical" drugs was eventually created (Fig.  6a) . In the next analysis, we extracted two compound groups (that contain 8 and 5 drugs, respectively) from the constructed network. Figure 6 illustrated that several connections in these two groups have been certified in previous studies (red edges). More broadly, an uncharacterized chemoresponse pattern of the two drugs RH1 and triethylenemelamine has been retrieved, which could interact with the behaviors of other drugs within the groups. The detection of compound links is propitious to direct the precise selection of anticancer drugs and refrain from the appearance of MDR in clinical cancer treatment.
Chemoresponse community database
Here, we presented the ChemoCommunity database as a novel and comprehensive resource for therapeutic biomarker discovery in cancer. ChemoCommunity collected detailed information about 5,688 compounds and their associated chemoresponse communities. With a user-friendly interface, users can query interested information in the "Compound" or "Community" section and download the used data and predicted results in the "Download" section. For example, through querying the interested compound in the "Compound" section of ChemoCommuntiy, users could not only gain the basic information of this compound but also achieve complete details of communities and molecules (includes genes and miRNAs) that are associated with its response. In addition, the community-linked drug pairs (potential multidrug resistance associations) are also provided in this inquiry. ChemoCommunity was developed using JSP, Tomcat 6.0.33 and MySQL 5.0 and runs under the CentOS 5.5 system. By facilitating the preclinical identification of putative therapeutic biomarkers, the ChemoCommunity database is a valuable resource that enables the development of rationally designed cancer therapeutic strategies incorporating molecular biomarkers.
Discussion
Compared with conventional single-molecule markers that were mainly filtered by differentially expressed analysis, community-based markers can implicate molecules with low distinguishing potential (that may be not significantly differentially expressed). Such nondiscriminative molecules can arise within a significant community if they are required to interconnect highly discriminative molecules and maintain the integrity of regulations in the community. This property is able to discover potential disease-causing molecules and increase the reproducibility of the identified markers. Additionally, we derived community markers from separate data cohorts and clearly demonstrated the robustness and reproducibility of using community-based markers over single-based markers for the predictors of the chemotherapy response. The improved performance of chemorepsonse community suggests that they may serve as better clinical predictors of drug response. Furthermore, chemoresponse community was able to uncover the mechanism of drug resistance systematically, which is not based on a single gene or miRNA, but rather on the aggregate behavior of molecules connected in the regulatory network. This feature is a significant departure from conventional individual gene analysis, which does not provide regulatory insight into the identified markers.
Through the systematic analysis of biological network, a series of chemoresponse communities were extracted to explain the regulatory mechanisms of drug responses. Comprehensive literature review revealed that most of these chemoresponse communities have been demonstrated to play important roles in mediating drug resistance. Especially, our communitybased method could interpret regulations of drug response in different ways. For example, chemoresponse community C28 could exert influence on responses to tamoxifen through regulating EGR1 and NFKB1 to induce dysregulation of cell apoptosis. In another way, through managing the CYP3A4, an enzyme of catalyzing tamoxifen metabolism, the chemoresponse of tamoxifen was also able to be affected by C38.
Even though several compound-community associations could not be readily explained on the basis of current understanding, they still reflect unappreciated biological relationships. C32 was predicted to be associated with resistance to immunosuppressive agents including MTX (p values 5 7.54 3 10 ), perhaps due to the decreased expression of CDKN2A, which is regulated by miR-24 in the cancer cell lines. Similarly, the dysregulation of C17, which is thought to depend on E2F4-induced changes in MYC expression, was related with sensitivity to the mTOR inhibitors everolimus (p values 5 1.02 3 10
23
) and sirolimus (p values 5 1.72 3 10 24 ). Even though the impact of many experimental compounds on tumor is not fully understood, the identified associations represented candidate biomarkers for compound sensitivity and could ultimately be useful for the development of targeted therapies in cancer.
To select more suitable therapeutic regimen for patients, we attempted to discover the potential MDR associations among compounds based on chemoresponse community. An attractive hypothesis is that two compounds with MDR associations tend to share analogous regulatory pathways and response patterns. Based on the above assumption, we identified possible compound pairs with MDR phenotype, whose common chemoresponse communities are significantly enriched. In this way, many validated MDR associations were found, such as the MDR relationship between mitomycin and MTX, which has been observed in cell assay and clinical report. More broadly, the potential chemoresponse pattern of the two uncharacterized drugs RH1 and triethylenemelamine was expounded in the MDR network analysis. The identification of drug response associations is propitious to direct the precise selection of anticancer drugs and refrain from the appearance of MDR in clinical cancer treatment.
High-throughput cancer cell line screening for chemotherapy response patterns provides a strategy for identifying appropriate cancer subtypes and biomarkers that could guide the early-phase clinical trials of multiple novel compounds under development. Additionally, it is widely accepted that modular structures exist in biological networks, which can be categorized as topological modules, functional modules and disease modules (or condition modules). 53 Based on multiple level data of cancer cell lines, our community-based approach could put these modular structures together to discover topological molecule sets in a functional regulation network filtered by condition-specific expression data. In the future, we will apply our method to prioritize effective biomarkers for drug response of clinical patients through integrating genomics data and clinical profiles. In conclusion, our networkbased algorithm, and the accompanying database, is propitious to identify novel type of drug resistance markers with excellent predictive performance, and improve the understanding of drug resistance mechanism in the view of transcriptional and post-transcriptional regulation.
